Table 2.
Effect of IGF-1 administration on osteoporosis and bone metabolism.
Authors | n. subjects | Age | Dosage μ/kg/day |
Duration | BF | BR | Clinical effects |
---|---|---|---|---|---|---|---|
Johansson et al., 1992 [262] | 1 M | — | 80 μ/kg/day × 2 | ↑ | ↑ | Bone formation markers increased | |
| |||||||
Ebeling et al., 1993 [263] | 18 PMO | 74 ± 0.2 66.3 ± 7.8 67.4 ± 5.5 58.6 ± 4.4 |
30 60 120 180 |
7 days | ↑ | ↑ | Significant dose-dependent BR, less BF. Longer treatments are suggested |
| |||||||
Rubin et al., 1994 [264] | 1 W, Werner syndrome, low serum IGF-1 level, and osteoporosis. | — | 30–75 | 6 months | ↑ | ↑ | Lumbar bone mass increased 3% BMD |
| |||||||
Grinspoon et al., 1995 [265] | 14 W normal | 19–33 | 100 μ × 2 | 6 days | ↑ | — | Increase bone formation |
| |||||||
Ghiron et al., 1995 [266] | 16 w healthy |
71.9 ± 1.3 | 60, 15 μ (diet also) | 28 days | ↑ | ↑ | Increase bone mass |
| |||||||
Johansson et al., 1996 [257] | 12 M IO | 44 ± 8 | 80 µ | 7 days | ↑ | ↑ | Enhanced bone formation and bone resorption |
| |||||||
Grinspoon et al., 1996 [267] | 23 W | 18–29 | 200, 60 µ | 6 days | ↑ | ↑ | Increases markers of bone turnover |
| |||||||
Mauras et al., 1996 [268] | 5 M + 3 W 3 M + 2 W |
23–27 23–25 |
240 µ
100 µ |
5–7 days | ↑ | ↑ | Synergize with sex steroids to maximally stimulate attainment of peak bone mass in humans |
| |||||||
Bianda et al., 1997 [245] | 7 M | 192 µ | 5 days | ↑ | ↑ | Serum osteocalcin and PICP, the urinary deoxypyridinoline/creatinine, and calcium/creatinine ratios got significantly higher | |
| |||||||
Berneis et al., 1999 [159] | 24 M healthy |
24.5 ± 1.2 | GH = 0.15 × 2 IU/kg/day + IGF-1 = 80 µ |
6 days | — | — | Markedly counteracts diminished bone and body collagen synthesis caused by glucocorticoids |
| |||||||
Friedlander et al., 2001 [269] | 24 PMO | 72 ± 2.7 | 15 µ/kg twice daily | 1 year | ↑ | ↑ | No effect |
| |||||||
Boonen et al., 2002 [270] | 30 W | 65–90 | 0.5–1 µ/kg/d | 8 weeks | ↑ | ↑ | Effects on bone mass, muscle strength, and functional ability, beneficial trends |
| |||||||
Grinspoon et al., 2002 [271] | 60 W osteopenia with anorexia |
18–38 | 30 μg/kg sc twice daily |
9 months | ↑ | — | Increased mIGFBP-2 and decreased IGFBP-3 and bone density increased |
| |||||||
Grinspoon et al., 2003 [272] | 65 W anorexia nervosa |
25.6 ± 0.8 | 30 μg/kg sc twice daily |
9 months | — | — | IGF-I and IGFBP-3 are independent predictors of bone density |
| |||||||
Misra et al., 2009 [273] | 10 W low bone density and anorexia |
12–18 | 30–40 mcg/k twice daily |
7–9 days | ↑ | ↑ | Increase in PINP, a bone formation marker |
M = men, W = women, PMO = postmenopausal women, MIO = men with idiopatic osteoporosis, BR = bone resorption, BF = bone formation.